Literature DB >> 25139782

Resistant or refractory hypertension: are they different?

Rodrigo Modolo1, Ana Paula de Faria, Aurélio Almeida, Heitor Moreno.   

Abstract

Resistant hypertension (RHTN) consists in a condition where blood pressure (BP) levels remain uncontrolled despite the use of at least three drugs or if the control happens with four or more drugs. Throughout the last 50 years, it has been increasingly studied, and its phenotypes have been identified. The term refractory hypertension has been used concurrently with RHTN all those years, but in the last decade, it has been applied to the most afflicted part of RHTN--defined as the uncontrolled RHTN or as the uncontrolled RHTN who needs five or more drugs. Differences between those two phenotypes are being recently identified, especially classifying refractory subjects as having more: (1) cardiovascular risk, (2) target organ damage, (3) African-descending race, (4) coronary heart disease and myocardial ischemia, (5) aldosterone excess, (6) deregulation of adipokines, and (7) possible sympathetic hyperactivation. We review the most important studies in both resistant and refractory hypertension to gather the up-to-date data regarding the characteristics of these two high-risk groups of patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25139782     DOI: 10.1007/s11906-014-0485-1

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  51 in total

1.  Hyperaldosteronism among black and white subjects with resistant hypertension.

Authors:  David A Calhoun; Mari K Nishizaka; Mohammad A Zaman; Roopal B Thakkar; Paula Weissmann
Journal:  Hypertension       Date:  2002-12       Impact factor: 10.190

2.  Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness.

Authors:  L C Martins; V N Figueiredo; T Quinaglia; L Boer-Martins; J C Yugar-Toledo; J F V Martin; C Demacq; E Pimenta; D A Calhoun; H Moreno
Journal:  J Hum Hypertens       Date:  2010-10-07       Impact factor: 3.012

3.  Resistant hypertension. Introduction and definitions.

Authors:  R W Gifford
Journal:  Hypertension       Date:  1988-03       Impact factor: 10.190

4.  The reasons for geographic and racial differences in stroke study: objectives and design.

Authors:  Virginia J Howard; Mary Cushman; Leavonne Pulley; Camilo R Gomez; Rodney C Go; Ronald J Prineas; Andra Graham; Claudia S Moy; George Howard
Journal:  Neuroepidemiology       Date:  2005-06-29       Impact factor: 3.282

5.  Resistant hypertension: demography and clinical characteristics in 6,292 patients in a primary health care setting.

Authors:  Teresa Gijón-Conde; Auxiliadora Graciani; José R Banegas
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2014-02-05

6.  Hypoadiponectinemia and aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertension.

Authors:  Ana P C de Faria; Caroline Demacq; Valéria N Figueiredo; Carolina H Moraes; Rodrigo C Santos; Andréa R Sabbatini; Natália R Barbaro; Leandro Boer-Martins; Vanessa Fontana; Heitor Moreno
Journal:  Hypertens Res       Date:  2013-08-22       Impact factor: 3.872

7.  Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines.

Authors:  Christine Guo; Vincent Ricchiuti; Bill Q Lian; Tham M Yao; Patricia Coutinho; José R Romero; Jianmin Li; Gordon H Williams; Gail K Adler
Journal:  Circulation       Date:  2008-04-21       Impact factor: 29.690

8.  Primary aldosteronism in diabetic subjects with resistant hypertension.

Authors:  Guillermo E Umpierrez; Paul Cantey; Dawn Smiley; Andres Palacio; Diana Temponi; Karen Luster; Arlene Chapman
Journal:  Diabetes Care       Date:  2007-04-11       Impact factor: 19.112

9.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

10.  Aldosterone excess or escape: Treating resistant hypertension.

Authors:  Samira Ubaid-Girioli; Leoní Adriana de Souza; Juan Carlos Yugar-Toledo; Luiz Cláudio Martins; Sílvia Ferreira-Melo; Otávio Rizzi Coelho; Cristina Sierra; Antonio Coca; Eduardo Pimenta; Heitor Moreno
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-05       Impact factor: 3.738

View more
  7 in total

1.  Predictors of Renal Denervation Efficacy in the Treatment of Resistant Hypertension.

Authors:  Tatiana M Ripp; Victor F Mordovin; Stanislav E Pekarskiy; Tamara R Ryabova; Marina V Zlobina; Andrei E Baev; Yana Anfinogenova; Sergey V Popov
Journal:  Curr Hypertens Rep       Date:  2015-12       Impact factor: 5.369

2.  [Therapy-resistant and therapy-refractory arterial hypertension].

Authors:  M Wallbach; M J Koziolek
Journal:  Internist (Berl)       Date:  2018-06       Impact factor: 0.743

3.  Brazilian Position Statement on Resistant Hypertension - 2020.

Authors:  Juan Carlos Yugar-Toledo; Heitor Moreno Júnior; Miguel Gus; Guido Bernardo Aranha Rosito; Luiz César Nazário Scala; Elizabeth Silaid Muxfeldt; Alexandre Alessi; Andrea Araújo Brandão; Osni Moreira Filho; Audes Diógenes de Magalhães Feitosa; Oswaldo Passarelli Júnior; Dilma do Socorro Moraes de Souza; Celso Amodeo; Weimar Kunz Sebba Barroso; Marco Antônio Mota Gomes; Annelise Machado Gomes de Paiva; Eduardo Costa Duarte Barbosa; Roberto Dischinger Miranda; José Fernando Vilela-Martin; Wilson Nadruz Júnior; Cibele Isaac Saad Rodrigues; Luciano Ferreira Drager; Luiz Aparecido Bortolotto; Fernanda Marciano Consolim-Colombo; Márcio Gonçalves de Sousa; Flávio Antonio de Oliveira Borelli; Sérgio Emanuel Kaiser; Gil Fernando Salles; Maria de Fátima de Azevedo; Lucélia Batista Neves Cunha Magalhães; Rui Manoel Dos Santos Póvoa; Marcus Vinícius Bolívar Malachias; Armando da Rocha Nogueira; Paulo César Brandão Veiga Jardim; Thiago de Souza Veiga Jardim
Journal:  Arq Bras Cardiol       Date:  2020 May-Jun       Impact factor: 2.000

Review 4.  Controlled Versus Uncontrolled Resistant Hypertension: Are They in the Same Bag?

Authors:  J C Yugar-Toledo; V Brunelli; J F Vilela-Martin; A Fattori; H Moreno
Journal:  Curr Hypertens Rep       Date:  2018-03-27       Impact factor: 5.369

5.  Refractory Hypertension: a Narrative Systematic Review with Emphasis on Prognosis.

Authors:  Giovanna Bacan; Angélica Ribeiro-Silva; Vinicius A S Oliveira; Claudia R L Cardoso; Gil F Salles
Journal:  Curr Hypertens Rep       Date:  2022-02-02       Impact factor: 5.369

Review 6.  Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.

Authors:  Juan Carlos Yugar-Toledo; Rodrigo Modolo; Ana Paula de Faria; Heitor Moreno
Journal:  Vasc Health Risk Manag       Date:  2017-10-16

7.  Resistant and refractory hypertension: two sides of the same disease?

Authors:  Elizabeth Silaid Muxfeldt; Bernardo Chedier; Cibele Isaac Saad Rodrigues
Journal:  J Bras Nefrol       Date:  2018-12-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.